*** * RECONNECTED TO U.S. Patent & Trademark Office * * * * * * SESSION RESUMED IN FILE 'USPAT' AT 12:30:16 ON 06 SEP 94
FILE 'USPAT' ENTERED AT 12:30:16 ON 06 SEP 94

=> s tumor?/ti or cancer?/ti or tumor?/ab or cancer?/ab

570 TUMOR?/TI

406 CANCER?/TI

2165 TUMOR?/AB

1175 CANCER?/AB

L3 3226 TUMOR?/TI OR CANCER?/TI OR TUMOR?/AB OR CANCER?/AB

=> s 13 and (oncogene?/ti or oncogene?/ab or oncoprotein?/ti or oncoprotein?/ab)
ONCOGENE?/TI

24

51 ONCOGENE?/AB

0 ONCOPROTEIN?/TI

3 ONCOPROTEIN?/AB

L4 20 L3 AND (ONCOGENE?/TI OR ONCOGENE?/AB OR ONCOPROTEIN?/TI OR ONCOPROTEIN?/AB)

=> d 14 1-10

- 1. 5,334,723, Aug. 2, 1994, 2-piperidinecarboxylic acid derivative, oncogene suppressor and agent for obtaining revertants; Tsuneo Okonogi, et al., 546/298, 297 [IMAGE AVAILABLE]
- 2. 5,320,947, Jun. 14, 1994, Immune reactivity to expressed activated oncogenes for diagnosis of malignancy; Martin A. Cheever, et al., 435/29; 424/520; 435/7.1, 7.23, 240.1, 240.2; 530/351, 395 [IMAGE AVAILABLE]
- 3. 5,320,941, Jun. 14, 1994, DNA sequence encoding mas onhoogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom; Dallan Young, et al., 435/7.23, 6, 7.9, 960; 436/813 [IMAGE AVAILABLE]
- 4. 5,300,631, Apr. 5, 1994, Antibodies specific for either ras photo-oncogene encoded P21 proteins or ras oncogene encoded P21 proteins but not for both and method of producing same; Robert A. Weinberg, et al., 530/387.7; 435/70.21, 172.2, 240.27; 436/547, 548; 530/387.9, 388.24, 388.8, 388.85, 389.2, 389.7 [IMAGE AVAILABLE]
- 5. 5,294,627, Mar. 15, 1994, Directed biosynthesis of biologically active compounds; Bryon H. Arison, et al., 514/338, 397, 414, 444, 452; 546/270; 548/311.7, 463; 549/60, 363 [IMAGE AVAILABLE]
- 6. 5,284,856, Feb. 8, 1994, Oncogene -encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives; Ramchandra G. Naik, et al., 514/320, 318 [IMAGE AVAILABLE]
- 7. 5,283,256, Feb. 1, 1994, Cholesterol-lowering agents; Claude Dufresne, et al., 514/452; 435/254.1; 549/363 [IMAGE AVAILABLE]
- 8. 5,258,401, Nov. 2, 1993, Cholesterol lowering compounds; Gregory D. Berger, et al., 514/452, 228.2, 233.8, 253, 256, 321, 333, 338, 365, 374, 382, 397, 406, 414, 422; 546/187, 197, 256, 270; 548/204, 236, 253, 311.7, 364.4, 454, 455, 517, 518; 549/13, 23, 28, 58, 60, 229, 310, 363 [IMAGE AVAILABLE]
- 9. 5,156,841, Oct. 20, 1992, Anti-tumor vaccine; Ulf R. Rapp, 424/277.1; 514/21 [IMAGE AVAILABLE]
- 10. 5,084,556, Jan. 28, 1992, Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene; Eugene L. Brown, 424/85.1; 514/2, 8; 530/351, 402, 403, 404, 405 [IMAGE AVAILABLE] => d 14 2 cit ab

2. 5,320,947, Jun. 14, 1994, Immune reactivity to expressed activated oncogenes for diagnosis of malignancy; Martin A. Cheever, et al., 435/29; 424/520; 435/7.1, 7.23, 240.1, 240.2; 530/351, 395 [IMAGE AVAILABLE]

US PAT NO:

5,320,947 [IMAGE AVAILABLE]

L4: 2 of 20

ABSTRACT:

Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to in vitro exposure to a protein expression product of an activated oncogene or cancer -related gene associated with a malignancy, or detection of immunocomplexes formed between the protein expression product and antibodies in body fluid, allows the diagnosis of the presence of a malignancy. The present invention also discloses methods and compositions for treating a malignancy.

=> s recognin or malignin

8 RECOGNIN

8 MALIGNIN

L5 8 RECOGNIN OR MALIGNIN

- => d 15 1-8
- 1. 4,976,957, Dec. 11, 1990, Process for the production of recognins and their chemoreciprocals; Samuel Bogoch, 530/389.7; 424/9, 573; 436/530, 542, 547; 530/391.1, 814 [IMAGE AVAILABLE]
- 2. 4,840,915, Jun. 20, 1989, Method for diagnosing malignant tumors; Samuel Bogoch, 436/530, 543, 805, 811, 813, 824 [IMAGE AVAILABLE]
- 3. 4,624,932, Nov. 25, 1986, Recognins and their chemoreciprocals; Samuel Bogoch, 436/538, 530, 542, 543, 547; 530/389.7, 413, 417, 814, 827 [IMAGE AVAILABLE]
- 4. 4,624,931, Nov. 25, 1986, Recognins and their chemoreciprocals; Samuel Bogoch, 436/528; 424/174.1; 435/7.23, 70.3, 961; 436/530, 531, 532; 530/300, 344, 350, 389.1, 389.7, 403 [IMAGE AVAILABLE] 5. 4,486,538, Dec. 4, 1984, Detection of malignant tumor cells; Samuel Bogoch, 424/156.1, 9, 178.1; 435/7.23, 29, 70.21, 172.2, 240.27; 436/503, 504, 548, 804, 813, 815; 514/908; 530/300, 388.85, 389.7, 809, 828; 935/103 [IMAGE AVAILABLE]
- 6. 4,298,590, Nov. 3, 1981, Detection of malignant tumor cells; Samuel Bogoch, 424/1.49; 128/653.1; 424/9; 435/7.23; 436/804; 530/300, 350, 380, 389.7, 391.3, 814, 828 [IMAGE AVAILABLE]
- 7. 4,196,186, Apr. 1, 1980, Method for diagnosing malignant gliol brain tumors; Samuel Bogoch, 436/503; 424/573; 435/7.23; 436/515, 530, 543; 514/21 [IMAGE AVAILABLE]
- 8. 4,195,017, Mar. 25, 1980, Malignin , derived from brain tumor cells, complexes and polypeptides thereof; Samuel Bogoch, 530/300; 424/573; 436/530, 543, 800, 804, 813; 530/389.7, 412, 417, 418, 422, 427, 812, 814, 838 [IMAGE AVAILABLE]